Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal and Abdominal Radiology 2020; 3(S 01): S58-S64
DOI: 10.1055/s-0040-1708024
Case Report

Hereditary Tyrosinemia Type 1—A Rare Disease with Typical Radiological Features: Case Report and Review of Literature

Somesh Singh
1   Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
,
Rana Vishwadeep Mall
1   Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
,
Pragya Chaturvedi
1   Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
,
Rajnikant R. Yadav
1   Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Hereditary tyrosinemia type 1 is one of the many inborn errors of metabolism associated with tyrosine catabolism. It is a rare disease with its incidence or prevalence in India unknown. The cascading alternate metabolism results in characteristic injury patterns to the liver, kidneys, and the central nervous system, with resultant classical radiological findings. Identifying this constellation of imaging features by a radiologist may help in arriving at a diagnosis and help referring physicians in performing appropriate biochemical tests and instituting early treatment. These usually present with chronic liver failure and are extensively evaluated for other causes of liver failure. We present a case type 1 hereditary tyrosinemia with characteristic radiological features and highlight its pathophysiology to understand the basis of these imaging findings.

Keywords

hepatocellular carcinoma - hereditary tyrosinemia type 1 - imaging - succinylacetoacetate


Publication History

Article published online:
18 May 2020

© 2020. Indian Society of Gastrointestinal and Abdominal Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Orphanet. Tyrosinemia type 1. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=882. Accessed on November 22, 2019
  • 2 Mohamed S, Kambal MA, Al Jurayyan NA. et al. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes 2013; 6: 362 DOI: 10.1186/1756-0500-6-362.
    CrossrefPubMedGoogle Scholar
  • 3 Oh MS, Hwang G, Han S. et al. Sonographic growth charts for kidney length in Normal Korean children: a prospective observational study. J Korean Med Sci 2016; 31 (07) 1089-1093
    CrossrefPubMedGoogle Scholar
  • 4 Udawat P, Gupta RK. Shambhavi, Sitaraman S. Tyrosinemia type 1: a case report and review of literature. Indian Journal of Medical Case Reports 2016; 5 (01) 9-12
    Google Scholar
  • 5 Chinsky JM, Singh R, Ficicioglu C. et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med 2017; 19 (12) 1380
    CrossrefPubMedGoogle Scholar
  • 6 Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Valle D, Beaudet AL, Vogelstein B. et al, eds. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2014
    Google Scholar
  • 7 Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976; 88 (03) 434-438
    CrossrefPubMedGoogle Scholar
  • 8 van Spronsen FJ, Thomasse Y, Smit GP. et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994; 20 (05) 1187-1191
    CrossrefPubMedGoogle Scholar
  • 9 Mitchell G, Larochelle J, Lambert M. et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990; 322 (07) 432-437
    CrossrefPubMedGoogle Scholar
  • 10 Alobaidy H, Barkaoui E. Experience of a single center in NTBC use in management of hereditary tyrosinemia type I in Libya. Iran J Pediatr 2015; 25 (05) e3608
    CrossrefPubMedGoogle Scholar
  • 11 Solanki S, Dave K. Imaging spectrum of tyrosinemia: a rare metabolic disease entity. Poster presented at: EPOS, Congress: European Congress of Radiology; 2015, Poster No: C-0028 2015
  • 12 Castilloux J, Laberge AM, Martin SR, Lallier M, Marchand V. “Silent” tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl. J Pediatr Gastroenterol Nutr 2007; 44 (03) 375-377
    CrossrefPubMedGoogle Scholar
  • 13 Sener RN. Brain magnetic resonance imaging in tyrosinemia. Acta Radiol 2005; 46 (06) 618-620
    CrossrefPubMedGoogle Scholar
  • 14 Dubois J, Garel L, Patriquin H. et al. Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients. Pediatr Radiol 1996; 26 (12) 845-851
    CrossrefPubMedGoogle Scholar
  • 15 Masurel-Paulet A, Poggi-Bach J, Rolland MO. et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008; 31 (01) 81-87
    CrossrefPubMedGoogle Scholar
  • 16 Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014; 37 (05) 745-752
    CrossrefPubMedGoogle Scholar
  • 17 Food and Drug Administration. Investigations operations manual 2015 Appendix C. Blood serum chemistry—normal values https://www.fda.gov/media/75935/download. Accessed on November 22, 2019